News + Filings Key Docs Ownership
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Medicenna Therapeutics Corp. (MDNA)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/10/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
10/03/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
09/28/2023 |
6-K
| Quarterly results |
09/28/2023 |
6-K
| Quarterly results |
08/14/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
08/09/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
08/08/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
08/04/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
08/01/2023 |
6-K
| Quarterly results |
07/28/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
07/25/2023 |
6-K
| Quarterly results |
07/06/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
|
"FORM 6-K",
"Medicenna Extends Period to Exercise Certain Warrants TORONTO and HOUSTON, July 05, 2023 -- Medicenna Therapeutics Corp. , a clinical stage immunotherapy company, today announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of a total of 1,549,052 outstanding common share purchase warrants of the Company originally issued on October 17, 2019 as part of a public offering of units of the Company. Each warrant is exercisable for a common share of the Company at a price of $1.75 per Common Share and set to expire on July 17, 2023. The Company has extended the expiry date of such Warrants until October 17, 2024, with such extension being effective on July 17, 2023. All other terms of the Warrants, including the exercise price, remain unchan..." |
|
04/27/2023 |
6-K
| Quarterly results |
04/18/2023 |
6-K
| Quarterly results |
04/17/2023 |
6-K
| Quarterly results |
03/30/2023 |
6-K
| Quarterly results |
03/15/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
03/02/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
02/28/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
02/14/2023 |
SC 13G/A
| Merchant Fahar reports a 25.7% stake in Medicenna Therapeutics Corp. |
02/07/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
01/31/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
01/26/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
01/05/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
11/10/2022 |
6-K
| Quarterly results |
11/04/2022 |
6-K
| Quarterly results |
10/28/2022 |
6-K
| Quarterly results |
10/25/2022 |
6-K
| Quarterly results |
10/20/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
10/17/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
10/05/2022 |
6-K
| Quarterly results |
09/30/2022 |
6-K
| Quarterly results |
09/28/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
09/22/2022 |
6-K
| Quarterly results |
|
|
|